Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $24.84 USD
Change Today -0.23 / -0.92%
Volume 40.8K
DYAX On Other Exchanges
As of 10:08 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

dyax corp (DYAX) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/8/15 - $30.55
52 Week Low
07/29/14 - $8.58
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DYAX CORP (DYAX)

dyax corp (DYAX) Related Bloomberg News

View More Bloomberg News

dyax corp (DYAX) Related Businessweek News

No Related Businessweek News Found

dyax corp (DYAX) Details

Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. It offers KALBITOR for the treatment of acute attacks of HAE. The company distributes KALBITOR through a network of wholesale, hospital, and specialty pharmacy arrangements. It is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b clinical study to treat HAE prophylactically. The company has agreements with CVie Therapeutics to develop and commercialize KALBITOR for the treatment of HAE and other angioedema indications in China, Hong Kong, and Macau; and Novellus Biopharma AG to develop and commercialize KALBITOR for the treatment of HAE and other angioedema indications in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela. It also has agreement with CMIC Co., Ltd. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other angioedema indications in Japan; and collaboration agreement with Sigma-Tau Rare Diseases S.A. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other therapeutic indications in various territories worldwide. Dyax Corp. was founded in 1989 and is headquartered in Burlington, Massachusetts.

124 Employees
Last Reported Date: 02/27/15
Founded in 1989

dyax corp (DYAX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $636.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $391.9K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $449.2K
Executive Vice President, General Counsel and...
Total Annual Compensation: $359.6K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $239.3K
Compensation as of Fiscal Year 2014.

dyax corp (DYAX) Key Developments

Dyax Corp. to Report Q2, 2015 Results on Jul 29, 2015

Dyax Corp. announced that they will report Q2, 2015 results at 5:00 PM, US Eastern Standard Time on Jul 29, 2015

Dyax Corp., Q2 2015 Earnings Call, Jul 29, 2015

Dyax Corp., Q2 2015 Earnings Call, Jul 29, 2015

Dyax Corp. Receives FDA Breakthrough Therapy Designation for DX-2930 for Prevention of Attacks of Hereditary Angioedema

Dyax Corp. announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for the investigation of DX-2930 for hereditary angioedema (HAE). Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein (pKal), as a subcutaneous injection for prevention of HAE attacks. Breakthrough Therapy designation is intended to expedite the development and review of potential new medicines with early signal of clinical benefit in serious or life-threatening conditions and helps ensure patients have access to them as soon as possible. Breakthrough Therapy designation is considered when preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available therapy. The benefits of Breakthrough Therapy designation include organizational commitment involving the FDA’s senior managers and with more intensive guidance. Breakthrough Therapy designation does not change the standards for approval. The designation is supported by the interim results of Dyax’s Phase 1b clinical trial of DX-2930 in HAE patients. The Phase 1b study met all objectives assessing safety, tolerability and pharmacokinetics of multiple subcutaneous administrations of DX-2930. Additionally, in a pre-specified proof-of-concept efficacy analysis, DX-2930 demonstrated statistically significant reductions in attack rate compared to placebo. DX-2930 is a novel, fully human monoclonal antibody inhibitor of pKal which is currently being developed as a subcutaneous injection for the prevention of HAE attacks. Uncontrolled pKal activity leads to excessive generation of bradykinin, a vasodilator thought to be responsible for the localized swelling, inflammation and pain characteristically associated with HAE.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DYAX:US $24.84 USD -0.23

DYAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioCryst Pharmaceuticals Inc $15.44 USD -0.28
Regeneron Pharmaceuticals Inc $548.68 USD -3.77
Shire PLC 5,740 GBp +135.00
View Industry Companies

Industry Analysis


Industry Average

Valuation DYAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 38.4x
Price/Book 33.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 37.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYAX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at